Author:
Lamborn Kathleen R.,Yung W. K. Alfred,Chang Susan M.,Wen Patrick Y.,Cloughesy Timothy F.,DeAngelis Lisa M.,Robins H. Ian,Lieberman Frank S.,Fine Howard A.,Fink Karen L.,Junck Larry,Abrey Lauren,Gilbert Mark R.,Mehta Minesh,Kuhn John G.,Aldape Kenneth D.,Hibberts Janelle,Peterson Pamela M.,Prados Michael D.
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Neurology (clinical),Oncology
Reference7 articles.
1. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, Food and Drug Administration. FDA Project on Cancer Drug Approval Endpoints. Last updated April 20, 2007. Available at http://www.fda.gov/cder/drug/cancer_endpoints. Accessed January 10, 2008.
2. Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83: 588-593.
3. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for Industry, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2007. Available at http://www.fda.gov/cder/guidance/7478fnl.pdf. Accessed January 10, 2008.
4. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17: 2572-2578.
5. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8: 1277-1280.
Cited by
362 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献